003 Atypical bullous pemphigoid due to radiation therapy
نویسندگان
چکیده
Introduction: Both breast cancer and radiation therapy (RT) have been associated with an increased risk of bullous pemphigoid (BP). In the setting RT, majority patients develop BP following completion treatment, a mean time to onset 15.8 months1. Case Report: A 68-year-old Black female history ductal carcinoma right status post partial mastectomy sentinel lymph node biopsy RT was referred Oncodermatology over two years after completing oncologic treatment for painful erosive blisters that developed in inframammary fold extension left breast. Physical exam showed clustered vesicles erosions overlying annular pink patches isolated folds. addition, beefy red gingival erythema observed. Herpes simplex virus testing superficial wound culture were performed, as well punch biopsies routine staining direct immunofluorescence testing. The differential diagnosis included delayed radiation-induced pemphigoid, irritant or allergic contact dermatitis, infection such impetigo herpes virus. Treatment triamcinolone 0.1% cream mupirocin ointment initiated. Biopsy findings focal subepidermal clefting studies linear IgG weak, patchy C3 at dermoepidermal junction. BP180 normal, BP230 elevated 39, IgE 278. patient diagnosed atypical breasts, most likely trigger given localization irradiated adjacent skin. improved topical corticosteroids systemic therefore deferred. Discussion: Atypical presentations localized triggered by may present should be on inflammatory dermatoses previously References: 1Nguyen T, Kwan JM, Ahmed AR. Relationship between Radiation Therapy Bullous Pemphigoid. J. Dermatol. 2014;229:88–96.
منابع مشابه
Bullous pemphigoid during ustekinumab therapy
BP: Bullous pemphigoid TNF-a: tumor necrosis factor-alfa INTRODUCTION Ustekinumab, a monoclonal antibody that blocks interleukin-12 and interleukin-23, is a biological therapy used to treat moderate-to-severe psoriasis. Bullous pemphigoid (BP) induced by antietumor necrosis factor-alfa (TNF-a) agents has been described in the literature. No cases have been reported with ustekinumab. We report a...
متن کاملDevelopment of bullous pemphigoid during nivolumab therapy
Bregs: B regulatory cells BP: bullous pemphigoid CTLA-4: cytotoxic T-lymphocyteeassociated protein 4 IRAE: immune-related adverse events PD-1: programmed cell death protein 1 PD-L1: programmed death ligand
متن کاملA new approach on bullous pemphigoid therapy.
Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering skin disease seen in the elderly. The prognosis of BP is poor, since the 1-year mortality rate has been reported to range from 25% to 40% in recent studies [1]. Corticosteroids have been so far the mainstay of therapy [2]. Antibiotics and immunosuppressants, such as cyclophosphamide and azathioprine, have also been us...
متن کاملBullous pemphigoid
Disease summary: Bullous Pemphigoid is an acquired, chronic, blistering autoimmune subepidermal bullous disease in which autoantibodies are directed against component of basement membrane zone of the skin [1]. It is characterized by formation of cutaneous bullae on the skin and mucous membrane. The pathogenesis involves migration of inflammatory cells into subepithilial tissues due to activatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Investigative Dermatology
سال: 2022
ISSN: ['1523-1747', '0022-202X']
DOI: https://doi.org/10.1016/j.jid.2022.05.057